|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||40.04 - 42.62|
|52 Week Range||23.41 - 58.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2022 - Mar 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.00|
SOMERSET, N.J., January 04, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, will deliver the company presentation on Tuesday, January 11, 2022 at 2:15 p.m. (Eastern Time).
SOMERSET, N.J., December 30, 2021--Legend Biotech appoints Dr. Ying Huang, CEO and CFO, to its board of directors.
SOMERSET, N.J., December 16, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public offering of 7,500,000 American depositary shares ("ADSs"), each representing two ordinary shares, at a public offering price of $40.00 per ADS, for total gross proceeds of approximately $300.0 m